Biotechnology News and Research

RSS

Stem cells and cancer: cancer pathways that also control the adult stem cell population

Speaking at the UK National Stem Cell Network Annual Science Meeting in Edinburgh, Professor Alan Clarke from Cardiff University described his work to investigate a mechanism that normally drives adult stem cells to repair the intestine.

11 Apr 2008

Manipulating the immune system like a parasite

One day it may be possible to mimic the tactics used by parasites to trick the body into accepting transplanted tissues or organs.

10 Apr 2008

Tiny scaffolding inserted into brain could reduce damage caused by strokes

Inserting tiny scaffolding into the brain could dramatically reduce damage caused by strokes the UK National Stem Cell Network Annual Science Meeting will hear today (10 April).

10 Apr 2008

Skin product decreases malignant melanoma tumor growth according to study

A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

8 Apr 2008

Clinical trial to test a novel HIV/AIDS vaccine

This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

4 Apr 2008

Appendix removed through a patient's vagina

On March 26, 2008, surgeons at UC San Diego Medical Center removed an inflamed appendix through a patient's vagina, a first in the United States.

From Evident Corporation - Life Sciences 31 Mar 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008

MRI opens up promising new avenues for non-invasive diagnoses and classification of cancer

Doctors diagnose and prescribe treatment for brain tumors by studying, under a microscope, tumor tissue and cell samples obtained through invasive biopsy or surgery.

25 Mar 2008

PharmAthene signs agreement to acquire biodefense vaccines business from Avecia

PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, has announced that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business.

24 Mar 2008

Novel approach may lead to safer delivery of genetic therapies

A novel strategy for circumventing safety problems that have plagued gene therapy has been offered by a complex multicenter group of researchers, including Professor Claudio Napoli, a Full Professor at the II University of Naples and Adjunct Professor at the Sbarro Research Institute for Cancer Research and Molecular Medicine and the Center of Biotechnology at the College of Science and Technology of Temple University.

24 Mar 2008

A polyphenols-rich diet keeps the heart younger

This finding comes out from a study by the University of Grenoble in collaboration with the other Centres participating to the FLORA Project, a European Commission funded research studying the effects of flavonoids, a variety of polyphenols, on human health.

24 Mar 2008

Skin patch gives bird flu vaccine a big boost

Researchers testing an experimental skin patch designed to boost an H5N1 vaccine say preliminary results have been promising.

21 Mar 2008

Natural biomedicines from the ocean

With the number of terrestrial sources that yield novel treatments for human disease decreasing year by year, the oceans have been tapped as a promising resource for discovering new natural biomedicines.

20 Mar 2008

Botulinum toxin, Quo Vadis?

The journal Medical Hypotheses, an Elsevier publication, has announced the winner of the 2007 David Horrobin Prize for medical theory.

19 Mar 2008

Silencing gene in tobacco plants reduces harmful carcinogens

In large-scale field trials, scientists from North Carolina State University have shown that silencing a specific gene in burley tobacco plants significantly reduces harmful carcinogens in cured tobacco leaves.

19 Mar 2008

Pain receptor in brain may be linked to learning and memory

Scientists have long known that the nervous system receptor known as TRPV1 can affect sensations of pain in the body.

14 Mar 2008

Lilly and Transition Therapeutics announce licensing and collaboration agreement

Eli Lilly and Company and Transition Therapeutics Inc. has announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.

14 Mar 2008

DuPont no. 1 innovator in chemical and biotech patents

DuPont has achieved top rankings in science and patent strength according to several leading indicators published by The Patent Board and Nature Biotechnology.

13 Mar 2008

Humble cup of tea inhibits anthrax

A cup of black tea could be the next line of defence in the threat of bio-terrorism according to new international research.

13 Mar 2008

Anadis licenses antibody technologies from ImmuCell

Anadis Limited, an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation, a biotechnology company headquartered in Portland, Maine, USA.

11 Mar 2008